Pathophysiology of levodopa-induced dyskinesia: potential for new therapies
E Bezard, JM Brotchie, CE Gross - Nature Reviews Neuroscience, 2001 - nature.com
Involuntary movements—or dyskinesias—are a debilitating complication of levodopa
therapy for Parkinson's disease that is experienced by most patients. Despite the importance …
therapy for Parkinson's disease that is experienced by most patients. Despite the importance …
Levodopa‐induced dyskinesias
G Fabbrini, JM Brotchie, F Grandas… - … : official journal of the …, 2007 - Wiley Online Library
Levodopa‐induced dyskinesias (LID) are common and difficult to treat. This review focuses
on three issues related to LID: clinical features, classification and rating, pathophysiology …
on three issues related to LID: clinical features, classification and rating, pathophysiology …
Presymptomatic compensation in Parkinson's disease is not dopamine-mediated
E Bezard, CE Gross, JM Brotchie - Trends in neurosciences, 2003 - cell.com
The symptoms of Parkinson's disease (PD) appear only after substantial degeneration of the
dopaminergic neuron system (eg an 80% depletion of striatal dopamine)–that is, there is a …
dopaminergic neuron system (eg an 80% depletion of striatal dopamine)–that is, there is a …
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine …
The concept of a threshold of dopamine (DA) depletion for onset of Parkinson's disease
symptoms, although widely accepted, has, to date, not been determined experimentally in …
symptoms, although widely accepted, has, to date, not been determined experimentally in …
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study
The lateral segment of the globus pallidus (GPl) is thought to be overactive in levodopa-
induced dyskinesia in PD. Stimulation of cannabinoid receptors in the GPl reduces γ …
induced dyskinesia in PD. Stimulation of cannabinoid receptors in the GPl reduces γ …
The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease
Abstract l-3, 4-Dihydroxyphenylalanine (l-DOPA) remains the most effective symptomatic
treatment of Parkinson's disease (PD). However, long-term administration of l-DOPA is …
treatment of Parkinson's disease (PD). However, long-term administration of l-DOPA is …
Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease
In recent years, cannabinoid receptors and their endogenous ligands (endocannabinoids)
have been identified within the brain. The high density of CB1 cannabinoid receptors within …
have been identified within the brain. The high density of CB1 cannabinoid receptors within …
Animal models of α-synucleinopathy for Parkinson disease drug development
JB Koprich, LV Kalia, JM Brotchie - Nature Reviews Neuroscience, 2017 - nature.com
A major challenge in Parkinson disease (PD) will be to turn an emerging and expanding
pipeline of novel disease-modifying candidate compounds into therapeutics. Novel targets …
pipeline of novel disease-modifying candidate compounds into therapeutics. Novel targets …
Nondopaminergic mechanisms in levodopa‐induced dyskinesia
JM Brotchie - Movement disorders: official journal of the …, 2005 - Wiley Online Library
It has become increasingly apparent that Parkinson's disease involves many transmitter
systems other than dopamine. This nondopaminergic involvement impacts on the …
systems other than dopamine. This nondopaminergic involvement impacts on the …
The serotonergic system in Parkinson's disease
Although the cardinal manifestations of Parkinson's disease (PD) are attributed to a decline
in dopamine levels in the striatum, a breadth of non-motor features and treatment-related …
in dopamine levels in the striatum, a breadth of non-motor features and treatment-related …